Regulatory PathRegulatory requirements compared

Active substances

Betamethasone + Fusidic acid

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade nameStrengthForm · routePackPublic priceTypeCompanyStatus
CIDOCOMB20,1 mg/g,mg/gCream · Topical1 TubeSAR 23.10Generic · PrescriptionMiddle East Pharmaceutical Industries Co Ltd Avalon PharmaValid
FUCICORT 2% CREAM2,0.1 %,%Cream · Topical1 TubeSAR 38.50NCE · PrescriptionLeo PharmaValid
FUSIBACT-B CREAM2,0.1 %,%Cream · Topical1 TubeSAR 12.90Generic · PrescriptionJamjoom Pharmaceuticals Factory CompanyValid
FUSIBACT-B CREAM2,0.1 %,%Cream · Topical1 TubeSAR 25.80Generic · PrescriptionJamjoom Pharmaceuticals Factory CompanyValid
FUSIDERM B CREAM2,0.1 %,%Cream · Topical1 TubeSAR 11.65Generic · PrescriptionSPIMACO ADDWAEIHValid
FUSIZONE CREAM2,0.1 %,%Cream · Topical1 TubeSAR 8.45Generic · PrescriptionBATTERJEE PHARMACETICAL FACTORYValid
UCIDERM -B CREAM2,0.1 %,%Cream · Topical1 TubeSAR 10.45Generic · PrescriptionPHILADELPHIA PHARMACEUTICALValid
ZETACORT CREAM2,0.1 %,%Cream · Topical1 TubeSAR 11.65Generic · PrescriptionTabuk Pharmaceutical Manufacturing CompanyValid
FUCICORT CREAM2, 0.1 %Cream · Topical1 TubeSAR 19.25NCE · PrescriptionLeo PharmaWithdrawn by MAH · Not Marketed
FUCITOPIC CREAM 15 GM2, 0.1 %Cream · Topical15 TubeSAR 10.45Generic · PrescriptionJazeera Pharmaceutical Industries (JPI)Withdrawn by MAH · Not Marketed
Indications — CHI Daman Drug Formulary

ECZEMA

Canada Canada — marketed products (Health Canada)

BrandDINStrengthForm · routeCompany
FUCIBET024748832 % / W/W; 0.1 % / W/WCREAM · TOPICALLEO PHARMA INC

Prices — United States and England

SourceProduct as listedPriceUnit / packDate
NHS Drug TariffBetamethasone valerate 0.1% / Fusidic acid 2% cream£6.3830 gram1 Oct 2026
NHS Drug TariffBetamethasone valerate 0.1% / Fusidic acid 2% cream£12.7660 gram1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.